1-(2-fluoroethyl)-5-methyl-1H-pyrazole | 1443279-14-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(2-fluoroethyl)-5-methyl-1H-pyrazole
• 英文别名: 1-(2-fluoroethyl)-5-methylpyrazole
• CAS: 1443279-14-8
• 化学式: C₆H₉FN₂
• 分子量: 128.15
• InChiKey: NIPGQAQNIPHPCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.9
• 重原子数：
  9
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• [EN] SUBSTITUTED FUSED HETEROAROMATIC BICYCLIC COMPOUNDS AS KINASE INHIBITORS AND THE USE THEREOF<br/>[FR] COMPOSÉS BICYCLIQUES HÉTÉROAROMATIQUES FUSIONNÉS SUBSTITUÉS UTILISÉS EN TANT QU'INHIBITEURS DE KINASE ET LEUR UTILISATION
  申请人：IMPACT THERAPEUTICS INC

  公开号：WO2020259601A1

  公开（公告）日：2020-12-30

  The disclosure provides novel substituted fused heteroaromatic compounds as represented in Formula I, wherein A1-A6 and R1-R4 are defined herein. The compounds of Formula I are kinase inhibitors, especially ATR kinase inhibitors. Therefore, the compounds of the disclosure may be used to treat ATR-mediated diseases, disorders and conditions, such as cancer.

  该披露提供了新型的取代融合杂芳化合物，如公式I所示，其中A1-A6和R1-R4在此定义。公式I中的化合物是激酶抑制剂，特别是ATR激酶抑制剂。因此，该披露中的化合物可用于治疗ATR介导的疾病、疾病和症状，如癌症。
• [EN] A CLASS OF THIOPHENE FUSED N-HETEROCYCLIES, PREPARATION METHOD AND USE<br/>[FR] CLASSE DE N-HÉTÉROCYCLES FUSIONNÉS PAR DU THIOPHÈNE, PROCÉDÉ DE PRÉPARATION ET UTILISATION<br/>[ZH] 一类噻吩并氮杂环类化合物、制备方法和用途
  申请人：SHANGHAI RINGENE BIOPHARMA CO LTD

  公开号：WO2020200154A1

  公开（公告）日：2020-10-08

  本发明公开了一种如通式I所示的噻吩并氮杂环类结构、或其药学上可接受的盐、或其对映异构体、非对映异构体、互变异构体、溶剂化物、多晶型物或前药、其制备方法及在药学上的应用。
• SULFONAMIDE COMPOUNDS AS VOLTAGE GATED SODIUM CHANNEL MODULATORS
  申请人：LUPIN LIMITED

  公开号：US20170137415A1

  公开（公告）日：2017-05-18

  The present invention relates to the compound of Formula (I) wherein the substituents are as described herein, and their use in a medicine for the treatment of diseases, disorders associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. It further relates to the compounds herein and their pharmaceutically acceptable salts thereof, pharmaceutical compositions thereof useful in treating diseases, disorders, syndromes and/or conditions associated with the inhibition of Voltage-gated sodium channels (VGSC) particularly NaV1.7. The invention also relates to process for the preparation of the compounds of the invention.